Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 5.035
Filtrar
1.
Taiwan J Obstet Gynecol ; 63(5): 771-776, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39266164

RESUMO

OBJECTIVE: To present the ultrasound imaging and genetic diagnosis of a fetus with prenatal lethal form of Gaucher disease. CASE REPORT: A 37-year-old primiparous woman was pregnant at her 23 weeks of gestation and the prenatal fetal ultrasound revealed hydrops fetalis, cerebellum hypoplasia, and fetal immobility. The pregnancy was terminated due to major fetal anomaly, and whole exome sequencing (WES) analysis of fetal tissue and parental blood unveiled a pathogenic variant in exon 10 of the GBA gene (NM_001005741.3: c.1265T > G: p.L422R) originating from the mother. Additionally, a novel CNV (chr1: 155204785-155205635 deletion, 0.85 kb) spanning exon 10-12 in the GBA gene was identified from the father. This compound heterozygosity confirmed the diagnosis of prenatal lethal form of Gaucher disease and was informative for genetic counseling. CONCLUSION: WES is a powerful tool to detect pathogenic variants among fetuses with nonimmune hydrops fetalis and complex abnormality from prenatal ultrasound. Compound heterozygosity consisted of single nucleotide variants (SNV) and copy number variations (CNVs) may lead rare inherited metabolic disorders including prenatal lethal form of Gaucher disease.


Assuntos
Cerebelo , Variações do Número de Cópias de DNA , Sequenciamento do Exoma , Doença de Gaucher , Hidropisia Fetal , Ultrassonografia Pré-Natal , Humanos , Feminino , Doença de Gaucher/genética , Doença de Gaucher/diagnóstico , Doença de Gaucher/complicações , Gravidez , Adulto , Hidropisia Fetal/genética , Hidropisia Fetal/diagnóstico , Cerebelo/anormalidades , Cerebelo/diagnóstico por imagem , Heterozigoto , Malformações do Sistema Nervoso/genética , Malformações do Sistema Nervoso/diagnóstico , Polimorfismo de Nucleotídeo Único , Glucosilceramidase/genética , Deficiências do Desenvolvimento
2.
Nat Rev Neurol ; 20(9): 526-540, 2024 09.
Artigo em Inglês | MEDLINE | ID: mdl-39107435

RESUMO

An exciting development in the field of neurodegeneration is the association between the rare monogenic disorder Gaucher disease and the common complex disorder Parkinson disease (PD). Gaucher disease is a lysosomal storage disorder resulting from an inherited deficiency of the enzyme glucocerebrosidase, encoded by GBA1, which hydrolyses the glycosphingolipids glucosylceramide and glucosylsphingosine. The observation of parkinsonism in a rare subgroup of individuals with Gaucher disease first directed attention to the role of glucocerebrosidase deficiency in the pathogenesis of PD. PD occurs more frequently in people heterozygous for Gaucher GBA1 mutations, and 3-25% of people with Parkinson disease carry a GBA1 variant. However, only a small percentage of individuals with GBA1 variants develop parkinsonism, suggesting that the penetrance is low. Despite over a decade of intense research in this field, including clinical and radiological evaluations, genetic studies and investigations using model systems, the mechanism underlying GBA1-PD is still being pursued. Insights from this association have emphasized the role of lysosomal pathways in parkinsonism. Furthermore, different therapeutic strategies considered or developed for Gaucher disease can now inform drug development for PD.


Assuntos
Doença de Gaucher , Glucosilceramidase , Doença de Parkinson , Doença de Gaucher/genética , Humanos , Doença de Parkinson/genética , Glucosilceramidase/genética , Animais , Mutação/genética
3.
Medicine (Baltimore) ; 103(34): e39354, 2024 Aug 23.
Artigo em Inglês | MEDLINE | ID: mdl-39183396

RESUMO

RATIONALE: Gaucher disease (GD) is a rare hereditary lysosomal storage disorder disease progression and inappropriate treatment. However, not all patients with GD receive timely diagnosis and treatment. PATIENT CONCERNS: Early diagnosis is important for initiating proper treatment and preventing complications. DIAGNOSES: Two patients were diagnosed as GD in this study. INTERVENTIONS AND OUTCOMES: These 2 patients received the imiglucerase enzyme replacement and symptoms significantly improved by the follow-up. LESSONS: Herein, we report 2 patients with a delayed diagnosis of GD to increase awareness and improve education regarding rare diseases. However, noninvasive ß-glucocerebrosidase activity or GBA gene testing had not been done before bone marrow aspiration, which are the noninvasive and reliable tests that indicate the diagnosis of GD.


Assuntos
Diagnóstico Tardio , Doença de Gaucher , Esplenomegalia , Trombocitopenia , Adulto , Humanos , Terapia de Reposição de Enzimas/métodos , Doença de Gaucher/diagnóstico , Doença de Gaucher/genética , Doença de Gaucher/complicações , Esplenomegalia/etiologia , Trombocitopenia/diagnóstico
4.
Proc Natl Acad Sci U S A ; 121(34): e2320257121, 2024 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-39150784

RESUMO

Lysosomal degradation pathways coordinate the clearance of superfluous and damaged cellular components. Compromised lysosomal degradation is a hallmark of many degenerative diseases, including lysosomal storage diseases (LSDs), which are caused by loss-of-function mutations within both alleles of a lysosomal hydrolase, leading to lysosomal substrate accumulation. Gaucher's disease, characterized by <15% of normal glucocerebrosidase function, is the most common LSD and is a prominent risk factor for developing Parkinson's disease. Here, we show that either of two structurally distinct small molecules that modulate PIKfyve activity, identified in a high-throughput cellular lipid droplet clearance screen, can improve glucocerebrosidase function in Gaucher patient-derived fibroblasts through an MiT/TFE transcription factor that promotes lysosomal gene translation. An integrated stress response (ISR) antagonist used in combination with a PIKfyve modulator further improves cellular glucocerebrosidase activity, likely because ISR signaling appears to also be slightly activated by treatment by either small molecule at the higher doses employed. This strategy of combining a PIKfyve modulator with an ISR inhibitor improves mutant lysosomal hydrolase function in cellular models of additional LSD.


Assuntos
Fibroblastos , Glucosilceramidase , Doenças por Armazenamento dos Lisossomos , Lisossomos , Fosfatidilinositol 3-Quinases , Humanos , Fosfatidilinositol 3-Quinases/metabolismo , Lisossomos/metabolismo , Lisossomos/efeitos dos fármacos , Glucosilceramidase/metabolismo , Glucosilceramidase/genética , Fibroblastos/metabolismo , Fibroblastos/efeitos dos fármacos , Doenças por Armazenamento dos Lisossomos/tratamento farmacológico , Doenças por Armazenamento dos Lisossomos/genética , Doenças por Armazenamento dos Lisossomos/metabolismo , Doença de Gaucher/tratamento farmacológico , Doença de Gaucher/genética , Doença de Gaucher/metabolismo , Inibidores de Fosfoinositídeo-3 Quinase/farmacologia
5.
Gene Ther ; 31(9-10): 439-444, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39147866

RESUMO

Almost all attempts to date at gene therapy approaches for monogenetic disease have used the amino acid sequences of the natural protein. In the current study, we use a designed, thermostable form of glucocerebrosidase (GCase), the enzyme defective in Gaucher disease (GD), to attempt to alleviate neurological symptoms in a GD mouse that models type 3 disease, i.e. the chronic neuronopathic juvenile subtype. Upon injection of an AAVrh10 (adeno-associated virus, serotype rh10) vector containing the designed GCase (dGCase) into the left lateral ventricle of Gba-/-;Gbatg mice, a significant improvement in body weight and life-span was observed, compared to injection of the same mouse with the wild type enzyme (wtGCase). Moreover, a reduction in levels of glucosylceramide (GlcCer), and an increase in levels of GCase activity were seen in the right hemisphere of Gba-/-;Gbatg mice, concomitantly with a significant improvement in motor function, reduction of neuroinflammation and a reduction in mRNA levels of various genes shown previously to be elevated in the brain of mouse models of neurological forms of GD. Together, these data pave the way for the possible use of modified proteins in gene therapy for lysosomal storage diseases and other monogenetic disorders.


Assuntos
Dependovirus , Modelos Animais de Doenças , Doença de Gaucher , Terapia Genética , Vetores Genéticos , Glucosilceramidase , Animais , Doença de Gaucher/terapia , Doença de Gaucher/genética , Glucosilceramidase/genética , Glucosilceramidase/metabolismo , Camundongos , Vetores Genéticos/genética , Vetores Genéticos/administração & dosagem , Dependovirus/genética , Terapia Genética/métodos , Glucosilceramidas/metabolismo , Humanos
6.
Int J Mol Sci ; 25(16)2024 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-39201273

RESUMO

Type 1 Gaucher disease (GD1) is a rare, autosomal recessive disorder caused by glucocerebrosidase deficiency. Skeletal manifestations represent one of the most debilitating and potentially irreversible complications of GD1. Although imaging studies are the gold standard, early diagnostic/prognostic tools, such as molecular biomarkers, are needed for the rapid management of skeletal complications. This study aimed to identify potential protein biomarkers capable of predicting the early diagnosis of bone skeletal complications in GD1 patients using artificial intelligence. An in silico study was performed using the novel Therapeutic Performance Mapping System methodology to construct mathematical models of GD1-associated complications at the protein level. Pathophysiological characterization was performed before modeling, and a data science strategy was applied to the predicted protein activity for each protein in the models to identify classifiers. Statistical criteria were used to prioritize the most promising candidates, and 18 candidates were identified. Among them, PDGFB, IL1R2, PTH and CCL3 (MIP-1α) were highlighted due to their ease of measurement in blood. This study proposes a validated novel tool to discover new protein biomarkers to support clinician decision-making in an area where medical needs have not yet been met. However, confirming the results using in vitro and/or in vivo studies is necessary.


Assuntos
Biomarcadores , Quimiocina CCL3 , Doença de Gaucher , Aprendizado de Máquina , Doença de Gaucher/metabolismo , Doença de Gaucher/diagnóstico , Doença de Gaucher/complicações , Humanos , Biomarcadores/sangue , Quimiocina CCL3/sangue , Quimiocina CCL3/metabolismo , Doenças Ósseas/etiologia , Doenças Ósseas/diagnóstico
7.
Biomolecules ; 14(7)2024 Jul 12.
Artigo em Inglês | MEDLINE | ID: mdl-39062556

RESUMO

Background: Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the GBA1 gene, leading to ß-glucocerebrosidase deficiency and glucosylceramide accumulation. Methods: We analyzed short- and long-term dynamics of lyso-glucosylceramide (lyso-Gb1) in a large cohort of GD patients undergoing enzyme replacement therapy (ERT). Results: Eight-years analysis of lyso-Gb1 revealed statistically insignificant variability in the biomarker across the years and relatively high individual variability in patients' results. GD type 1 (GD1) patients exhibited higher variability compared to GD type 3 (GD3) patients (coefficients of variation: 34% and 23%, respectively; p-value = 0.0003). We also investigated the short-term response of the biomarker to enzyme replacement therapy (ERT), measuring lyso-Gb1 right before and 30 min after treatment administration. We tested 20 GD patients (16 GD1, 4 GD3) and observed a rapid and significant reduction in lyso-Gb1 levels (average decrease of 17%; p-value < 0.0001). This immediate response reaffirms the efficacy of ERT in reducing substrate accumulation in GD patients but, on the other hand, suggests the biomarker's instability between the infusions. Conclusions: These findings underscore lyso-Gb1's potential as a reliable biomarker for monitoring efficacy of treatment. However, individual variability and dry blood spot (DBS) testing limitations urge a further refinement in clinical application. Our study contributes valuable insights into GD patient management, emphasizing the evolving role of biomarkers in personalized medicine.


Assuntos
Terapia de Reposição de Enzimas , Doença de Gaucher , Glucosilceramidase , Humanos , Doença de Gaucher/tratamento farmacológico , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Glucosilceramidase/genética , Glucosilceramidase/uso terapêutico , Adolescente , Adulto Jovem , Biomarcadores/sangue , Criança , Psicosina/metabolismo , Psicosina/análogos & derivados , Idoso , Pré-Escolar
9.
Semin Musculoskelet Radiol ; 28(4): 505-510, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39074730

RESUMO

Gaucher's disease (GD) is a lysosomal storage disorder characterized by the storage of glucosylceramide in macrophages ("Gaucher cells"), mainly in the reticuloendothelial system. GD type 1 (GD1) is the most common phenotype that usually manifests with hepatosplenomegaly, cytopenias, and bone involvement. Skeletal manifestations are the most debilitating characteristic and result in significant morbidities. We describe a case of GD1, first presented by a nontraumatic bone fracture. The case presentation highlights the importance of considering GD among the differential diagnosis of nontraumatic fractures, avascular necrosis, and infarcts of the bones. Early diagnosis and treatment improve the course of disease and avoid irreversible sequelae.


Assuntos
Doença de Gaucher , Humanos , Doença de Gaucher/diagnóstico por imagem , Doença de Gaucher/complicações , Diagnóstico Diferencial , Masculino , Imageamento por Ressonância Magnética/métodos , Adulto
10.
Chem Biodivers ; 21(8): e202401104, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38847390

RESUMO

A remarkable enhancer of human glucocerebrosidase enzyme (GCase) was identified among a set of dihydroazulene-tagged iminosugars. An unprecedented 3.9-fold increase in GCase activity was detected on fibroblasts bearing the homozygous L444P mutation, which is frequently associated with neuronopathic Gaucher forms, and which commonly results refractory to chaperone-induced refolding.


Assuntos
Glucosilceramidase , Mutação , Humanos , Glucosilceramidase/metabolismo , Glucosilceramidase/genética , Glucosilceramidase/antagonistas & inibidores , Imino Açúcares/química , Imino Açúcares/farmacologia , Imino Açúcares/síntese química , Imino Açúcares/metabolismo , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Doença de Gaucher/genética , Doença de Gaucher/tratamento farmacológico , Doença de Gaucher/metabolismo , Estrutura Molecular
11.
Sci Adv ; 10(26): eadk1296, 2024 Jun 28.
Artigo em Inglês | MEDLINE | ID: mdl-38924406

RESUMO

Mutations in GBA1 cause Gaucher disease and are the most important genetic risk factor for Parkinson's disease. However, analysis of transcription at this locus is complicated by its highly homologous pseudogene, GBAP1. We show that >50% of short RNA-sequencing reads mapping to GBA1 also map to GBAP1. Thus, we used long-read RNA sequencing in the human brain, which allowed us to accurately quantify expression from both GBA1 and GBAP1. We discovered significant differences in expression compared to short-read data and identify currently unannotated transcripts of both GBA1 and GBAP1. These included protein-coding transcripts from both genes that were translated in human brain, but without the known lysosomal function-yet accounting for almost a third of transcription. Analyzing brain-specific cell types using long-read and single-nucleus RNA sequencing revealed region-specific variations in transcript expression. Overall, these findings suggest nonlysosomal roles for GBA1 and GBAP1 with implications for our understanding of the role of GBA1 in health and disease.


Assuntos
Glucosilceramidase , Pseudogenes , Humanos , Glucosilceramidase/genética , Glucosilceramidase/metabolismo , Pseudogenes/genética , Encéfalo/metabolismo , Anotação de Sequência Molecular , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , Doença de Gaucher/genética , Análise de Sequência de RNA/métodos
12.
Bone ; 186: 117142, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38834102

RESUMO

Gaucher disease is one of the most common lysosomal storage disorders. Osteonecrosis is a principal clinical manifestation of Gaucher disease and often leads to joint collapse and fractures. T1-weighted (T1w) modality in MRI is widely used to monitor bone involvement in Gaucher disease and to diagnose osteonecrosis. However, objective and quantitative methods for characterizing osteonecrosis are still limited. In this work, we present a deep learning-based quantification approach for the segmentation of osteonecrosis and the extraction of characteristic parameters. We first constructed two independent U-net models to segment the osteonecrosis and bone marrow unaffected by osteonecrosis (UBM) in spine and femur respectively, based on T1w images from patients in the UK national Gaucherite study database. We manually delineated parcellation maps including osteonecrosis and UBM from 364 T1w images (176 for spine, 188 for femur) as the training datasets, and the trained models were subsequently applied to all the 917 T1w images in the database. To quantify the segmentation, we calculated morphological parameters including the volume of osteonecrosis, the volume of UBM, and the fraction of total marrow occupied by osteonecrosis. Then, we examined the correlation between calculated features and the bone marrow burden score for marrow infiltration of the corresponding image, and no strong correlation was found. In addition, we analyzed the influence of splenectomy and the interval between the age at first symptom and the age of onset of treatment on the quantitative measurements of osteonecrosis. The results are consistent with previous studies, showing that prior splenectomy is closely associated with the fractional volume of osteonecrosis, and there is a positive relationship between the duration of untreated disease and the quantifications of osteonecrosis. We propose this technique as an efficient and reliable tool for assessing the extent of osteonecrosis in MR images of patients and improving prediction of clinically important adverse events.


Assuntos
Aprendizado Profundo , Doença de Gaucher , Imageamento por Ressonância Magnética , Osteonecrose , Doença de Gaucher/diagnóstico por imagem , Doença de Gaucher/patologia , Humanos , Osteonecrose/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Masculino , Feminino , Adulto , Fêmur/diagnóstico por imagem , Fêmur/patologia , Pessoa de Meia-Idade , Processamento de Imagem Assistida por Computador/métodos , Adolescente , Adulto Jovem , Medula Óssea/diagnóstico por imagem , Medula Óssea/patologia
13.
Parkinsonism Relat Disord ; 124: 107023, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38843618

RESUMO

INTRODUCTION: Gaucher's disease (GD) is caused by biallelic mutations in the GBA1 gene, leading to reduced glucocerebrosidase (GCase) activity and substrate (glucosylceramide and glucosylsphingosine, GlcSph) accumulation. GBA1 variant carriers are at risk of Parkinson's disease (PD), but only those with biallelic mutations cross the threshold of GCase reduction, leading to substrate accumulation and GD. The link between GBA1 mutations, GD and PD is not fully understood. Here we aimed at reporting the results of a large PD population screening with dried blood spot tests for GD. METHODS: We measured GCase activity and GlcSph levels in 1344 PD patients with dried blood spot tests, and performed GBA1 genetic sequencing. RESULTS: While the GCase activity was reduced in GBA1-PD carriers compared to wild type PD, GlcSph was increased in GBA1-PD compared to GBA1-controls, regardless of the underlying type of GBA1 variant. 13.6 % and 0.4 % of PD patients had mono- or biallelic GBA1 mutations respectively. GCase deficiency, lipid accumulation and clinical manifestations of GD was detected in five PD patients with biallelic GBA1 mutations, of whom four had a risk combined with a GD causing variant. CONCLUSIONS: GlcSph appearing higher in PD may represent a reliable biomarker of the disease and deserves to be further investigated. This study highlights the importance of screening PD patients for possible underlying GD, which is a treatable condition that should not be missed. We diagnosed GD cases carrying a "risk" variant in one allele, which is an unprecedented finding deserving further investigation.


Assuntos
Doença de Gaucher , Glucosilceramidase , Doença de Parkinson , Psicosina , Humanos , Glucosilceramidase/genética , Doença de Gaucher/genética , Doença de Gaucher/sangue , Doença de Parkinson/genética , Doença de Parkinson/sangue , Psicosina/análogos & derivados , Psicosina/sangue , Masculino , Feminino , Idoso , Pessoa de Meia-Idade , Mutação , Teste em Amostras de Sangue Seco , Adulto , Idoso de 80 Anos ou mais
14.
Int J Mol Sci ; 25(12)2024 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-38928321

RESUMO

Glucocerebrosidase (GCase) is a lysosomal enzyme that catalyzes the breakdown of glucosylceramide in the presence of its activator saposin C (SapC). SapC arises from the proteolytical cleavage of prosaposin (encoded by PSAP gene), which gives rise to four saposins. GCase is targeted to the lysosomes by LIMP-2, encoded by SCARB2 gene. GCase deficiency causes Gaucher Disease (GD), which is mainly due to biallelic pathogenetic variants in the GCase-encoding gene, GBA1. However, impairment of GCase activity can be rarely caused by SapC or LIMP-2 deficiencies. We report a new case of LIMP-2 deficiency and a new case of SapC deficiency (missing all four saposins, PSAP deficiency), and measured common biomarkers of GD and GCase activity. Glucosylsphingosine and chitotriosidase activity in plasma were increased in GCase deficiencies caused by PSAP and GBA1 mutations, whereas SCARB2-linked deficiency showed only Glucosylsphingosine elevation. GCase activity was reduced in fibroblasts and leukocytes: the decrease was sharper in GBA1- and SCARB2-mutant fibroblasts than PSAP-mutant ones; LIMP-2-deficient leukocytes displayed higher residual GCase activity than GBA1-mutant ones. Finally, we demonstrated that GCase mainly undergoes proteasomal degradation in LIMP-2-deficient fibroblasts and lysosomal degradation in PSAP-deficient fibroblasts. Thus, we analyzed the differential biochemical profile of GCase deficiencies due to the ultra-rare PSAP and SCARB2 biallelic pathogenic variants in comparison with the profile observed in GBA1-linked GCase deficiency.


Assuntos
Doença de Gaucher , Glucosilceramidase , Proteínas de Membrana Lisossomal , Receptores Depuradores , Saposinas , Glucosilceramidase/genética , Glucosilceramidase/deficiência , Glucosilceramidase/metabolismo , Humanos , Doença de Gaucher/genética , Doença de Gaucher/metabolismo , Saposinas/deficiência , Saposinas/genética , Saposinas/metabolismo , Proteínas de Membrana Lisossomal/metabolismo , Proteínas de Membrana Lisossomal/genética , Receptores Depuradores/genética , Receptores Depuradores/metabolismo , Fibroblastos/metabolismo , Mutação , Lisossomos/metabolismo , Lisossomos/enzimologia , Hexosaminidases/metabolismo , Hexosaminidases/genética , Hexosaminidases/deficiência , Masculino , Feminino
15.
Mol Genet Metab ; 142(4): 108515, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38909587

RESUMO

Gaucher disease (GD) is a lysosomal storage disorder with glucocerebroside accumulation in the macrophages. The disease is divided into three types based on neurocognitive involvement with GD1 having no involvement while the acute (GD2) and chronic (GD3) are neuronopathic. The non-neurological symptoms of GD3 are well treated with enzyme replacement therapy (ERT) which has replaced hematopoietic stem cell transplantation (HSCT). ERT is unable to prevent neurological progression as the enzyme cannot cross the blood-brain barrier. In this retrospective study, we report the general, neurocognitive, and biochemical outcomes of three siblings with GD3 after treatment with ERT or HSCT. Two were treated with HSCT (named HSCT1 and HSCT2) and one with ERT (ERT1). All patients were homozygous for the c.1448 T > C, (p.Leu483Pro) variant in the GBA1 gene associated with GD3. ERT1 experienced neurocognitive progression with development of seizures, oculomotor apraxia, perceptive hearing loss and mental retardation. HSCT1 had no neurological manifestations, while HSCT2 developed perceptive hearing loss and low IQ. Chitotriosidase concentrations were normal in plasma and cerebrospinal fluid (CSF) for HSCT1 and HSCT2, but both were markedly elevated in ERT1. We report a better neurological outcome and a normalization of chitotriosidase in the two siblings treated with HSCT compared to the ERT-treated sibling. With the advancements in HSCT over the past 25 years, we may reconsider using HSCT in GD3 to achieve a better neurological outcome and limit disease progression.


Assuntos
Terapia de Reposição de Enzimas , Doença de Gaucher , Glucosilceramidase , Transplante de Células-Tronco Hematopoéticas , Humanos , Doença de Gaucher/terapia , Doença de Gaucher/genética , Doença de Gaucher/tratamento farmacológico , Masculino , Feminino , Glucosilceramidase/genética , Glucosilceramidase/uso terapêutico , Estudos Retrospectivos , Criança , Resultado do Tratamento , Irmãos , Adolescente , Hexosaminidases/genética , Pré-Escolar
16.
Nat Nanotechnol ; 19(8): 1203-1215, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38740934

RESUMO

Nutrient avidity is one of the most distinctive features of tumours. However, nutrient deprivation has yielded limited clinical benefits. In Gaucher disease, an inherited metabolic disorder, cells produce cholesteryl-glucoside which accumulates in lysosomes and causes cell damage. Here we develop a nanoparticle (AbCholB) to emulate natural-lipoprotein-carried cholesterol and initiate Gaucher disease-like damage in cancer cells. AbCholB is composed of a phenylboronic-acid-modified cholesterol (CholB) and albumin. Cancer cells uptake the nanoparticles into lysosomes, where CholB reacts with glucose and generates a cholesteryl-glucoside-like structure that resists degradation and aggregates into microscale crystals, causing Gaucher disease-like damage in a glucose-dependent manner. In addition, the nutrient-sensing function of mTOR is suppressed. It is observed that normal cells escape severe damage due to their inferior ability to compete for nutrients compared with cancer cells. This work provides a bioinspired strategy to selectively impede the metabolic action of cancer cells by taking advantage of their nutrient avidity.


Assuntos
Doença de Gaucher , Lisossomos , Nanopartículas , Humanos , Doença de Gaucher/metabolismo , Doença de Gaucher/patologia , Nanopartículas/química , Lisossomos/metabolismo , Colesterol/metabolismo , Colesterol/química , Linhagem Celular Tumoral , Neoplasias/metabolismo , Neoplasias/patologia , Ácidos Borônicos/química , Glucose/metabolismo , Animais , Serina-Treonina Quinases TOR/metabolismo
17.
Hum Mol Genet ; 33(17): 1467-1480, 2024 Aug 18.
Artigo em Inglês | MEDLINE | ID: mdl-38757200

RESUMO

Gaucher Disease (GD) is an inherited metabolic disorder caused by mutations in the GBA1 gene. It can manifest with severe neurodegeneration and visceral pathology. The most acute neuronopathic form (nGD), for which there are no curative therapeutic options, is characterised by devastating neuropathology and death during infancy. In this study, we investigated the therapeutic benefit of systemically delivered AAV9 vectors expressing the human GBA1 gene at two different doses comparing a neuronal-selective promoter with ubiquitous promoters. Our results highlight the importance of a careful evaluation of the promoter sequence used in gene delivery vectors, suggesting a neuron-targeted therapy leading to high levels of enzymatic activity in the brain but lower GCase expression in the viscera, might be the optimal therapeutic strategy for nGD.


Assuntos
Dependovirus , Doença de Gaucher , Terapia Genética , Vetores Genéticos , Glucosilceramidase , Regiões Promotoras Genéticas , Doença de Gaucher/genética , Doença de Gaucher/terapia , Doença de Gaucher/patologia , Vetores Genéticos/genética , Terapia Genética/métodos , Humanos , Regiões Promotoras Genéticas/genética , Dependovirus/genética , Glucosilceramidase/genética , Glucosilceramidase/metabolismo , Animais , Camundongos , Encéfalo/metabolismo , Encéfalo/patologia , Neurônios/metabolismo , Neurônios/patologia , Técnicas de Transferência de Genes
18.
Neurochem Int ; 178: 105774, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38797393

RESUMO

Glucocerebrosidase (GCase), encoded by the GBA1 gene, is one of the lysosomal enzymes responsible for hydrolyzing the glycosphingolipids. Deficiency in GCase activity (in patients with two defective alleles of GBA1) leads to glucosylceramide storage in lysosomes which in turn results in the development of the Gaucher diseases, a lysosomal storage disorder, while a heterozygous state may be correlated with the GBA1 mutation-associated Parkinson disease. One of the proposed forms of therapy for these two conditions is the use of pharmacological chaperones which work by facilitating the achievement of the correct conformation of abnormally folded enzymes. Several compounds with chaperone activities against GCase have already been tested, one of which turned out to be ambroxol. Studies conducted on the action of this compound have indeed indicated its effectiveness in increasing GCase levels and activity. However, some data have begun to question its activity as a chaperone against certain GCase variants. Then, a number of articles appeared pointing to other mechanisms of action of ambroxol, which may also contribute to the improvement of patients' condition. This paper summarizes the biological mechanisms of action of ambroxol in Gaucher disease and GBA1 mutation-associated Parkinson disease, focused on its activity as a chaperone, modulator of ERAD pathways, inducer of autophagy, and pain reliever in cellular and animal models as well as in patients. The effects of these activities on the reduction of disease markers and symptoms in patients are also discussed. Consideration of all the properties of ambroxol can help in the appropriate choice of therapy and the determination of the effective drug dose.


Assuntos
Ambroxol , Doença de Gaucher , Glucosilceramidase , Mutação , Doença de Parkinson , Doença de Gaucher/tratamento farmacológico , Doença de Gaucher/genética , Doença de Gaucher/metabolismo , Ambroxol/farmacologia , Ambroxol/uso terapêutico , Humanos , Glucosilceramidase/genética , Glucosilceramidase/metabolismo , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , Animais
19.
Science ; 384(6701): 1220-1227, 2024 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-38753766

RESUMO

Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. The enhanced tropism was CNS-specific and absent in wild-type mice. When used to deliver GBA1, mutations of which cause Gaucher disease and are linked to Parkinson's disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared with AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.


Assuntos
Antígenos CD , Encéfalo , Capsídeo , Técnicas de Transferência de Genes , Vetores Genéticos , Glucosilceramidase , Receptores da Transferrina , Animais , Humanos , Camundongos , Antígenos CD/metabolismo , Antígenos CD/genética , Barreira Hematoencefálica/metabolismo , Encéfalo/metabolismo , Capsídeo/metabolismo , Proteínas do Capsídeo/metabolismo , Proteínas do Capsídeo/genética , Dependovirus , Células Endoteliais/metabolismo , Técnicas de Introdução de Genes , Terapia Genética , Receptores da Transferrina/metabolismo , Receptores da Transferrina/genética , Glucosilceramidase/genética , Doença de Gaucher/genética , Doença de Gaucher/terapia , Doença de Parkinson/genética , Doença de Parkinson/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA